Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy. [electronic resource]
Producer: 20200914Description: 5850-5861 p. digitalISSN:- 2045-7634
- Adenocarcinoma of Lung -- drug therapy
- Antineoplastic Agents -- therapeutic use
- B7-H1 Antigen -- antagonists & inhibitors
- ErbB Receptors -- genetics
- Gene Expression Regulation, Neoplastic
- Humans
- Immunotherapy
- Lung Neoplasms -- drug therapy
- Mutation
- Neoplasm Staging
- Prognosis
- Risk Assessment
- Survival Analysis
- Tumor Suppressor Protein p53 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.